Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,384 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06257030 | The AMARA (As Much As Reasonably Achievable) Study | recruiting | — | 100 | University Hospital of PatrasOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT06189833 | Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS(TAURUS) | unknown | Phase 2 | 200 | Stichting European Myeloma NetworkNETWORK | 5 |
| Apr 23, 2024 |
| clinicaltrials |
| NCT06380010 | Mediterranean Diet Intervention in Adolescents With Polycystic Ovary Syndrome | completed | N/A | 40 | Iaso Maternity Hospital, Athens, GreeceOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT03935763 | Management of Metastatic Colorectal Cancer: A Clinical and Patient Perspective(PROMETCO) | unknown | — | 738 | Servier Affaires MédicalesINDUSTRY | 18 | Apr 22, 2024 | clinicaltrials |
| NCT06007001 | Telerehabilitation and Tele-psychological Support in Cancer Patients eCAN JA(eCAN) | unknown | N/A | 354 | SciensanoOTHER_GOV | 10 | Apr 19, 2024 | clinicaltrials |
| NCT04128072 | Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma(MOGAT) | recruiting | Phase 2 | 43 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | Apr 5, 2024 | clinicaltrials |
| NCT02928406 | A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract | completed | Phase 3 | 1,004 | Hoffmann-La RocheINDUSTRY | 32 | Apr 4, 2024 | clinicaltrials |
| NCT03450057 | Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment(DARE) | completed | Phase 2 | 38 | Hellenic Society of HematologyOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT06049693 | Iron Prehabilitation in Endometrial Cancer(IROGYN) | completed | Phase 4 | 156 | National and Kapodistrian University of AthensOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT06103526 | Immunonutrition in ERAS Protocols in Gynecologic Oncology(NUTRIGO) | unknown | N/A | 200 | National and Kapodistrian University of AthensOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT02603432 | A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100) | completed | Phase 3 | 700 | PfizerINDUSTRY | 29 | Mar 27, 2024 | clinicaltrials |
| NCT04177108 | A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer | completed | Phase 3 | 242 | Hoffmann-La RocheINDUSTRY | 37 | Mar 27, 2024 | clinicaltrials |
| NCT03125902 | A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)(IMpassion131) | completed | Phase 3 | 653 | Hoffmann-La RocheINDUSTRY | 24 | Mar 26, 2024 | clinicaltrials |
| NCT04197986 | Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations(PROOF302) | terminated | Phase 3 | 39 | QED Therapeutics, a BridgeBio companyINDUSTRY | 11 | Mar 13, 2024 | clinicaltrials |
| NCT02278120 | Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer(MONALEESA-7) | completed | Phase 3 | 672 | Novartis PharmaceuticalsINDUSTRY | 30 | Mar 12, 2024 | clinicaltrials |
| NCT03337724 | A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer(IPATunity130) | completed | Phase 3 | 579 | Hoffmann-La RocheINDUSTRY | 30 | Mar 12, 2024 | clinicaltrials |
| NCT03770468 | Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma | completed | — | 599 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Mar 8, 2024 | clinicaltrials |
| NCT00330447 | Effects of Oncological Treatment During Pregnancy on Mother and Child | recruiting | — | 5,000 | University Hospital, GasthuisbergOTHER | 20 | Mar 6, 2024 | clinicaltrials |
| NCT02013167 | Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) | terminated | Phase 3 | 405 | AmgenINDUSTRY | 21 | Mar 5, 2024 | clinicaltrials |
| NCT04492371 | COVID-19 Infection and Multiple Myeloma(EMN-COVID) | completed | — | 1,054 | Stichting European Myeloma NetworkNETWORK | 8 | Mar 5, 2024 | clinicaltrials |
| NCT01120184 | A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) | completed | Phase 3 | 1,095 | Hoffmann-La RocheINDUSTRY | 38 | Mar 4, 2024 | clinicaltrials |
| NCT05797727 | Real-Life Pilot Feasibility Study (LC_RLP)(LC_RLP) | completed | N/A | 121 | Aristotle University Of ThessalonikiOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT03222895 | Distribution of Lymph Node Metastases in Esophageal Carcinoma(TIGER) | recruiting | — | 5,000 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 14 | Feb 13, 2024 | clinicaltrials |
| NCT03834220 | Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial) | terminated | Phase 2 | 63 | Debiopharm International SAINDUSTRY | 23 | Feb 7, 2024 | clinicaltrials |
| NCT05179122 | Effectiveness of Wound Drains for the Prevention Of Surgical sITe infectION(POSITION) | completed | N/A | 200 | National and Kapodistrian University of AthensOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT03151811 | A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide(OCEAN) | terminated | Phase 3 | 495 | Oncopeptides ABINDUSTRY | 21 | Jan 30, 2024 | clinicaltrials |
| NCT01281735 | International Chronic Myeloid Leukemia Pediatric Study(ICMLPed) | recruiting | — | 750 | Poitiers University HospitalOTHER | 20 | Jan 17, 2024 | clinicaltrials |
| NCT05406687 | Cancer Prevention and Early Detection Among the Homeless Population: The Health Navigator Model(CANCERLESS) | completed | N/A | 654 | Medical University of ViennaOTHER | 4 | Jan 8, 2024 | clinicaltrials |
| NCT05795374 | Nutritional and Functional Assessment of Patients Undergoing Surgery Due to Gastrointestinal Cancer (NUFAGI).(NUFAGI) | completed | — | 300 | Maximos FrountzasOTHER | 1 | Dec 28, 2023 | clinicaltrials |
| NCT04151563 | A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy(CheckMate 79X) | withdrawn | Phase 1 / Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 10 | Dec 19, 2023 | clinicaltrials |
| NCT05444972 | A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review(METER) | completed | — | 998 | AbbVieINDUSTRY | 14 | Dec 11, 2023 | clinicaltrials |
| NCT05280275 | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | unknown | Phase 1 / Phase 2 | 36 | Hellenic Society of HematologyOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT05964621 | Venous Thromboembolism in Primary Pancreatic Tumour Resection(PaTR-VTE) | unknown | — | 64 | University of ThessalyOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT05270044 | Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.(COLUMBUS-AD) | active not recruiting | Phase 3 | 815 | Pierre Fabre MedicamentINDUSTRY | 23 | Nov 22, 2023 | clinicaltrials |
| NCT02369016 | Phase III Copanlisib in Rituximab-refractory iNHL(CHRONOS-2) | completed | Phase 3 | 25 | BayerINDUSTRY | 10 | Nov 18, 2023 | clinicaltrials |
| NCT02312206 | The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis(VITAL) | terminated | Phase 3 | 260 | Prothena Biosciences Ltd.INDUSTRY | 15 | Nov 14, 2023 | clinicaltrials |
| NCT06125353 | The Effect of Melatonin Supplementation on Fatigue Symptoms During Chemotherapy Treatment of Breast Cancer Patients | completed | N/A | 56 | Harokopio UniversityOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT03750786 | A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer(AGENT) | completed | Phase 3 | 490 | Isofol Medical ABINDUSTRY | 10 | Oct 26, 2023 | clinicaltrials |
| NCT02941926 | Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC(COMPLEEMENT-1) | completed | Phase 3 | 3,246 | Novartis PharmaceuticalsINDUSTRY | 38 | Oct 24, 2023 | clinicaltrials |
| NCT04808037 | Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma(BelaRd) | active not recruiting | Phase 1 / Phase 2 | 66 | Hellenic Society of HematologyOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT05573802 | A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 36 | Hellenic Society of HematologyOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT04721002 | Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)(MEDICI) | completed | — | 514 | AbbVieINDUSTRY | 22 | Oct 18, 2023 | clinicaltrials |
| NCT02125461 | A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer(PACIFIC) | completed | Phase 3 | 713 | AstraZenecaINDUSTRY | 26 | Oct 10, 2023 | clinicaltrials |
| NCT05727007 | CT and MRI in Preoperative Colon Cancer Staging | completed | N/A | 120 | Larissa University HospitalOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT06015087 | Evaluation of the Influence of Short Term Fasting Diet on Chemotherapy-induced Toxicities in Breast Cancer Patients | unknown | N/A | 50 | University of ThessalyOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT02312258 | A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT) | completed | Phase 3 | 706 | TakedaINDUSTRY | 35 | Sep 21, 2023 | clinicaltrials |
| NCT02741570 | Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck(CheckMate 651) | completed | Phase 3 | 947 | Bristol-Myers SquibbINDUSTRY | 18 | Sep 21, 2023 | clinicaltrials |
| NCT01485861 | Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy | completed | Phase 1 / Phase 2 | 298 | Genentech, Inc.INDUSTRY | 9 | Sep 14, 2023 | clinicaltrials |
| NCT06034782 | Diagnostic Accuracy of Fine Needle Aspiration in Patients With Salivary Gland Tumors. | completed | — | 128 | Aristotle University Of ThessalonikiOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT02426125 | A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer(RANGE) | completed | Phase 3 | 530 | Eli Lilly and CompanyINDUSTRY | 23 | Aug 21, 2023 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials